Global, Castration

Research and Markets Ireland United Kingdom United States of America

25.07.2017 - 16:47:21

Global Castration Resistant Prostate Cancer Treatment Market 2017-2021 - Physician's Preference Toward Hormonal Therapy Driving the Market

report has been added to Research and Markets' offering.

Research and Markets Logo

The global castration-resistant prostate cancer treatment market to grow at a CAGR of 9.01% during the period 2017-2021.

Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

One trend in the market is increasing consolidation in cancer treatment market. The oncology drugs industry has seen significant R&D and funding, which are largely responsible for the increasing consolidation of the industry. The rising trend of movement of cancer treatment from clinics to hospitals signifies the growing importance of strategic alliances and acquisition among the vendors.

According to the report, one driver in the market is physician's preference toward hormonal therapy. The abnormal growth in testosterone level characterizes prostate cancer. Therefore, hormone therapies, which control the secretion of this hormone and help reduce the growth of prostate cancer cells, remain the most sought-after therapy for treating CRPC. The proven efficacious profiles of these therapies with established clinical credentials have led to increased adoption among physicians. Hormonal therapies dominate the global CRPC treatment market and are expected to continue with the same during the forecast period.

Further, the report states that one challenge in the market is high cost of treatment. The high cost of treatment is a major problem for the CRPC patients across the globe. Many of the treatment options available for the individuals are out of their budget and ultimately forces the individual or the payer to skip the treatment. Virtual monopoly among the drug manufacturers and the high cost of R&D are some of the major factors for the high cost of CRPC treatment. A large proportion of population either skip the treatment or leave it in the middle.

Key vendors

Astellas PharmaJohnson & JohnsonSanofiValeant

Other prominent vendors

Active BiotechAdvaxisANI PharmaceuticalsAthenexBavarian NordicBayerBristol-Myers SquibbCureVacGlaxoSmithKlineInnocrin PharmaceuticalMerckMyovant SciencesNorthwest BiotherapeuticsOncoGenex PharmaceuticalsOncolytics BiotechOrionSotioTakeda PharmaceuticalTeva Pharmaceutical Industries

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market landscape

Part 06: Pipeline landscape

Part 07: Market segmentation by therapy

Part 08: Geographical segmentation

Part 09: Decision framework

Part 10: Drivers and challenges

Part 11: Market trends

Part 12: Vendor landscape

Part 13: Key vendor analysis

Part 14: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716



Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!